Pardes Biosciences
IPOPublic · Carlsbad · Founded 2020 · $51.6M raised
- Headquarters
- Carlsbad
- Employees
- 1–10
- Founded
- 2020
- Website
- pardesbio.com
- Total Funding
- $51.6M
- Last Round
- $51.6M Series AJan 2021
- Rounds
- 1
- Type
- Public
About
Pardes Biosciences was a clinical-stage biopharmaceutical company based in Carlsbad, California, founded in February 2020 by Dr. Uri Lopatin to develop oral antiviral therapeutics, including a protease inhibitor targeting COVID-19. The company went public via SPAC merger in December 2021, raising roughly $199 million to advance its antiviral pipeline, and entered a definitive merger agreement to be acquired by MediPacific, Inc. in July 2023.
Summary
Pardes Biosciences is a Biotech company based in Carlsbad, founded in 2020. It has raised $51.6M in total across 1 round, most recently a $51.6M Series A round in Jan 2021. Investors include Foresite Capital, FS Development Corp. II and Khosla Ventures.
Funding History
Aug 2023
Sign up to see all 3 rounds
Series A through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Specialty pharmaceutical company focused on addressing therapeutic needs in the fields of psychia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/pardesbio"><img src="https://indexed.vc/api/badge/company/pardesbio" alt="Pardes Biosciences on Indexed.vc" width="260" height="76" /></a>